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Abstract
Background—Perfluoroalkyl substances (PFASs) are widespread and persistent environmental
pollutants. Previous studies, primarily among non-pregnant individuals, suggest positive
associations between PFAS levels and certain blood lipids. If there is a causal link between PFAS
concentrations and elevated lipids during pregnancy, this may suggest a mechanism by which
PFAS exposure leads to certain adverse pregnancy outcomes, including preeclampsia.
Methods—This cross-sectional analysis included 891 pregnant women enrolled in the
Norwegian Mother and Child (MoBa) Cohort Study in 2003–2004. Non-fasting plasma samples
were obtained at mid-pregnancy and analyzed for nineteen PFASs. Total cholesterol, high-density
lipoprotein (HDL) cholesterol, low-density lipoprotein cholesterol, and triglycerides were
measured in plasma. Linear regression was used to quantify associations between each PFAS
exposure and each lipid outcome. A multiple PFAS model was also fitted.
Results—Seven PFASs were quantifiable in >50% of samples. Perfluorooctane sulfonate
(PFOS) concentration was associated with total cholesterol, which increased 4.2 mg/dL per
interquartile shift (95% CI=0.8, 7.7) in adjusted models. Five of the seven PFASs studied were
positively associated with HDL cholesterol, and all seven had elevated HDL associated with the
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highest quartile of exposure. Perfluoroundecanoic acid showed the strongest association with
HDL: HDL increased 3.7 mg/dL per interquartile shift (95% CI=2.5, 4.9).
Conclusion—Plasma concentrations of PFASs were positively associated with HDL cholesterol,
and PFOS was positively associated with total cholesterol in this sample of pregnant Norwegian
women. While elevated HDL is not an adverse outcome per se, elevated total cholesterol
associated with PFASs during pregnancy could be of concern if causal.
Keywords
The Norwegian Mother and Child Cohort Study; MoBa; perfluoroalkyl substances;
perfluorooctanoic acid; perfluorooctane sulfonate
1. Introduction
Perfluoroalkyl substances (PFASs1) are persistent environmental contaminants detectable in
the blood of human populations worldwide (Fromme et al., 2009; Kannan et al., 2004).
PFASs are used in the manufacturing process of numerous industrial and consumer
products, including surface treatments for fabrics and food packaging, fire-fighting foam,
surfactants and pesticide additives (Giesy and Kannan, 2002). They may enter the
environment through release from industrial sources or through consumer products
(Prevedouros et al., 2006).
Sources of exposure to PFASs in the general population may include food, drinking water,
house dust, air, and breast milk for infants (Fromme et al., 2010; Haug et al., 2011). PFASs
are highly resistant to degradation in the environment or metabolism in the body (Fromme et
al., 2009; Lau et al., 2007). The elimination half-lives of perfluorooctane sulfonate (PFOS),
perfluorohexane sulfonate (PFHxS), and perfluorooctanoate (PFOA) from human serum
have been estimated to be 4.8 years, 7.3 years, and 2.3 years, respectively (Bartell et al.,
2010; Olsen et al., 2007). The geometric mean elimination half-lives of PFOS and PFHxS
were estimated using serial serum measurements collected over three to five years in 26
former fluorochemical workers who had retired within four years of the beginning of the
study (Olsen et al., 2007). The median PFOA elimination half-life was estimated using serial
serum measurements from 200 individuals previously exposed to PFOA-contaminated
drinking water (Bartell et al., 2010). In that study, up to six serum samples were collected
during the 15 months following the installation of a granular activated carbon water
filtration system (Bartell et al., 2010). Both studies suggested that subject-specific
elimination rates may vary considerably (Bartell et al., 2010; Olsen et al., 2007). PFASs are
not lipophilic, and while the tissue distribution in humans is unknown, animal studies
suggest that PFASs likely reside primarily in the liver, kidneys, and blood (Kennedy et al.,
2004).
Animal studies have demonstrated a number of adverse health effects associated with high-
dose oral exposure to PFOS and PFOA, including hepatotoxicity, tumorigenesis,
immunotoxicity, and developmental toxicity (DeWitt et al., 2009; Lau et al., 2007). Some
adverse effects in animals are believed to be mediated through the binding of PFASs to the
peroxisome proliferator-activated receptor alpha (PPARα), which plays a role in the
regulation of lipid and glucose metabolism in humans and rodents (Abbott et al., 2007).
1Abbreviations: BMI, body mass index; CI, confidence interval; DAG, directed acyclic graph; HDL, high-density lipoprotein; IQR,
interquartile range; LDL, low-density lipoprotein; LOQ, limit of quantification; MBRN, Medical Birth Registry of Norway; MoBa,
Norwegian Mother and Child Cohort Study; PFASs, perfluoroalkyl substances; PFDA, perfluorodecanoic acid; PFHpS,
perfluoroheptane sulfonate; PFHxS, perfluorohexane sulfonate; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic acid; PFOS,
perfluorooctane sulfonate; PFUnDA, perfluoroundecanoic acid.
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In epidemiologic studies of highly exposed populations as well as populations with
background levels of exposure, PFAS concentrations have been associated with altered lipid
profiles that are consistent with increased risk of cardiovascular disease. These lipid
alterations have included elevated plasma cholesterol and triglycerides (Nelson et al., 2010;
Olsen et al., 2003; Steenland et al., 2009). The two PFASs typically present in human blood
at the highest concentrations, PFOS and PFOA, have been studied most extensively, but
recently researchers have begun to examine the lipid correlates of PFASs present at lower
concentrations, including PFHxS and perfluorononanoic acid (PFNA) (Fisher et al., 2013;
Nelson et al., 2010). The observed associations between PFASs and lipid concentrations
have not been consistent across studies or across populations, possibly owing to the different
age and sex distributions of the groups studied, the different sizes of the study populations,
or the different settings (occupational versus general populations).
To our knowledge, no previous studies of the associations between PFAS levels and plasma
lipid concentrations have been conducted among pregnant women. The relation between
PFASs and lipids during pregnancy is particularly important to quantify for the following
reasons: 1) environmental contaminants present in maternal blood may have adverse effects
on both the mother and developing fetus; 2) pregnant women differ in their relative and
absolute lipid concentrations (Piechota and Staszewski, 1992), and may show different
associations between PFASs and lipids as compared with non-pregnant women; and 3)
altered plasma lipids during pregnancy, particularly elevated plasma triglycerides, are
associated with a number of adverse outcomes, including preeclampsia (Sattar et al., 1997a)
and pregnancy-induced hypertension (Vrijkotte et al., 2012).
A retrospective study of pregnancy outcomes among women in Ohio and West Virginia
exposed to PFOA-contaminated drinking water found elevated odds of preeclampsia
associated with higher levels of PFOA (Savitz et al., 2012). If pregnant women with higher
PFAS levels demonstrate the same altered lipid patterns previously described in non-
pregnant populations, then this may suggest a mechanism by which plasma PFAS
concentrations could be linked to an increased risk of preeclampsia. In particular, elevations
in triglycerides and certain types of low-density lipoprotein (LDL) particles are considered
“pro-atherogenic” during pregnancy and may promote oxidative stress and endothelial
damage, leading to preeclampsia (Llurba et al., 2005).
We therefore measured cross-sectional associations between PFAS concentrations at
midpregnancy and the levels of the following lipid parameters: total cholesterol, LDL
cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides. The purpose of
this study was to increase understanding of the physiologic correlates of plasma PFAS
concentration during pregnancy and to evaluate a possible mechanism of any associations
that may exist between plasma PFAS concentrations and adverse pregnancy outcomes,
including preeclampsia.
2. Materials and Methods
2.1. Cohort description and eligibility criteria
The Norwegian Mother and Child Cohort Study (MoBa) is a prospective population-based
pregnancy cohort study conducted by the Norwegian Institute of Public Health (Magnus et
al., 2006; Nilsen et al., 2009; Ronningen et al., 2006). The study was approved by the
Regional Committee for Medical Research Ethics and the Norwegian Data Inspectorate.
Participants were recruited from all over Norway in 1999–2008. In total, 39% of invited
women participated. Informed consent was obtained from each MoBa participant upon
recruitment. At the time of enrollment, women provided information via questionnaire
regarding a number of demographic and lifestyle characteristics, as well as events in their
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reproductive and medical history. Blood samples were obtained from the mother during
pregnancy (median = 18 weeks of gestation). Data obtained in MoBa were linked to the
Medical Birth Registry of Norway (Irgens, 2000). Further details may be found at
www.fhi.no/morogbarn. The current study is based on version 4.301 of the quality-assured
data files released for research.
The current analysis uses data that were previously collected for a case-control study of
PFASs and subfecundity (Whitworth et al., 2012). For the previous study, 400 pregnancies
were randomly selected from all eligible MoBa participants who met the criteria for
subfecundity (defined as self-reported time to pregnancy of greater than 12 months), and
550 pregnancies were randomly selected from all eligible MoBa participants who reported a
time to pregnancy of any duration. To be eligible for selection into the previous study,
women must have enrolled in MoBa in 2003–2004, delivered a live-born child, provided a
mid-pregnancy plasma sample, and provided complete information about time to pregnancy
on the enrollment questionnaire.
From the 950 participants in the previous study, 891 women (94%) with complete
information on covariates and outcomes of interest were included in the present analysis.
Each of the individual covariates had missing data for <3% of participants. Participants
ranged in age from 19 to 44 (Table 1). Half of the women had no previous live births or
stillbirths (50%), while 3% had three or more previous pregnancies. A total of 8% reported
smoking during pregnancy. The range of gestational age at the time of blood draw was from
12 weeks to 37 weeks; however, the majority of women (99%) provided plasma samples
during their second trimester of pregnancy (14–26 weeks’ gestation), and 73% of
participants provided plasma samples between 17 and 20 weeks of gestation.
2.2. Collection and storage of plasma samples
At the time of study enrollment, maternal non-fasting blood samples were collected in
EDTA tubes at hospitals and maternity units across Norway and shipped at ambient
temperature to the MoBa biorepository in Oslo. Most samples were received and processed
the day after collection (Ronningen et al., 2006). At the biorepository, plasma was separated,
aliquoted, and stored at −80 degrees Celsius. Changes in PFAS concentrations in transit are
believed to be negligible, as PFASs are chemically stable (Fromel and Knepper, 2010), and
a recent study showed no evidence of change over time in concentrations of four PFASs in
serum maintained at room temperature for 10 days (Kato et al., 2013). Lipid concentrations
are also expected to be relatively unchanged during shipping; a previous study demonstrated
that lipid measurements changed by only a small percentage (<7% for LDL, <4% for HDL,
total cholesterol, and triglycerides) when whole blood was kept at room temperature (21
degrees Celsius) in EDTA tubes for up to 7 days (Clark et al., 2003).
2.3. Exposure measurement
Concentrations (ng/mL) of nineteen PFASs were measured in maternal plasma using high-
performance liquid chromatography/tandem mass spectrometry at the Norwegian Institute of
Public Health. Calibration solutions were prepared in serum from newborn calves using
PFAS standards purchased from Wellington Laboratories (Guelph, Ontario, Canada). The
calibration samples contained concentrations of PFASs ranging from 0.050 to 75 ng/mL
serum for all analytes. In brief, 150 µL of plasma from each participant or matrix-matched
calibration solution was transferred to a centrifugation tube and internal standards and
methanol were added and mixed. The samples were then centrifuged and the supernatant
was transferred to a glass autosampler vial, and 0.1 M formic acid was added and mixed.
The extracts were analyzed by injection of 400 µL on a column switching liquid
chromatography system coupled to a triple quadrupole mass spectrometer. A Betasil C8
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column (10 mm × 4 mm × 5 µm particles) from Thermo Scientific was used as the on-line
SPE column and a Betasil C8 (50 mm × 2.1 mm × 3 µm particles) from Thermo Scientific as
the analytical column. The limit of quantification (LOQ) was 0.05 ng/mL for all PFASs,
except for perfluorobutanoic acid (0.1 ng/mL), perfluorotetradecanoate (0.2 ng/mL) and
perfluorodecane sulfonate (0.2 ng/mL). Further details on the analytical method are
described elsewhere (Haug et al., 2009a).
Statistical analyses were restricted to the seven PFASs quantifiable in at least 50% of
samples: perfluorooctane sulfonate (PFOS), perfluoroheptane sulfonate (PFHpS),
perfluorohexane sulfonate (PFHxS), perfluorooctanoic acid (PFOA), perfluorononanoic acid
(PFNA), perfluorodecanoic acid (PFDA), and perfluoroundecanoic acid (PFUnDA). The
method blanks analyzed with each batch of samples did not contain any of the PFASs above
the LOQ. For quantification of PFOS, the total area of linear and branched isomers was
integrated (peaks not chromatographically separated). A total of 50 blinded, pooled
specimens were analyzed in the same batches as the sample specimens for quality assurance/
quality control (QA/QC) purposes. Inter-assay coefficients of variation were calculated for
each PFAS and are shown in Table 2.
2.4. Outcome measurement
Plasma lipid parameters (total cholesterol, HDL cholesterol, LDL cholesterol, and
triglycerides) were measured in the same mid-pregnancy, non-fasting plasma sample that
was used to evaluate PFAS concentrations. All analytes were measured with an Olympus
AU400e Clinical Chemistry Analyzer at the National Institute of Environmental Health
Sciences, using reagents from Beckman Coulter. The method used to measure LDL was
direct enzymatic (N-geneous® LDL-ST cholesterol reagent). Inter-assay coefficients of
variation were calculated for all lipid parameters based on the 50 QA/QC samples.
2.5. Covariates
Information on maternal characteristics was derived from the MoBa baseline questionnaire
and from the Medical Birth Registry of Norway (MBRN). Variables considered to be
potential confounders based on the prior literature were: maternal age (Chateau-Degat et al.,
2010; Fisher et al., 2013; Nelson et al., 2010; Steenland et al., 2009), pre-pregnancy body
mass index (BMI) (Fei et al., 2007), nulliparous or most recent interpregnancy interval (Fei
et al., 2007; Whitworth et al., 2012), duration of breastfeeding most recent child (Whitworth
et al., 2012), maternal years of education (Fisher et al., 2013; Steenland et al., 2009), current
smoking at mid-pregnancy (Chateau-Degat et al., 2010; Fisher et al., 2013; Nelson et al.,
2010; Steenland et al., 2009), gestational weeks at blood draw (Fei et al., 2007), and amount
of oily fish consumed daily at the time of the mid-pregnancy questionnaire (Brantsaeter et
al., 2013; Chateau-Degat et al., 2010). Weight gain (kg) from pre-pregnancy to mid-
pregnancy was calculated by subtracting the self-reported pre-pregnancy weight from the
self-reported current weight on the MoBa baseline questionnaire.
Additionally, for models with HDL cholesterol as the outcome, adjustment for plasma
albumin concentration (g/dL; quartiles) was considered due to the positive correlation
observed between HDL and plasma albumin. Albumin was measured in the mid-pregnancy
maternal plasma sample with an Olympus AU400e Clinical Chemistry Analyzer at the
National Institute of Environmental Health Sciences, using reagents from Beckman Coulter.
The method of measurement was direct and utilized a neutral buffered solution of
bromocresol green as a dye binding indicator.
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Weighted multiple linear regression was used to estimate the association between each
PFAS concentration and each lipid outcome. Weights were based on the inverse probability
of selection into the original case-control study (Whitworth et al., 2012), as described in
Richardson et al. (2007). A sensitivity analysis was performed to examine whether
restricting to the women who were selected without regard to subfecundity (the ‘base
sample’) would produce results that closely resembled the results of the weighted analysis.
Concentrations of PFASs were treated in two ways for the purposes of analysis: (1) as
quartiles, with the lowest quartile serving as the referent category (with the exception of
PFDA, which was categorized only at or above versus below the median due to >25% of
values below the limit of quantification) and (2) as natural-log transformed continuous
variables to assess linear trends. In models using quartiles of exposure, beta-coefficients
represent the change in lipid parameter (mg/dL or ln-mg/dL) associated with each of the
upper quartiles, relative to the lowest quartile of PFAS concentration. In models using
natural log-transformed continuous exposure variables, the beta-coefficients represent the
change in lipid concentration (mg/dL or ln-mg/dL) associated with each natural log-unit
increase in each PFAS. Additionally, the change in lipid concentration (mg/dL or ln-mg/dL)
associated with an interquartile-range (IQR) shift in each continuous ln-PFAS (from the 25th
percentile to the 75th percentile of the observed exposure distribution) is reported. For
PFDA, because more than 25% of values were below the LOQ, the IQR was estimated from
the observed portion of the log-normal distribution. For all PFASs, values below the LOQ
were replaced by the expected value of the log-normal distribution, given that the value was
below the limit of quantification; this was calculated as the mean of values below the limit
of quantification randomly drawn from the estimated log-normal distribution (Richardson
and Ciampi, 2003).
Each lipid parameter was treated as a continuous outcome variable in a separate model with
a single PFAS exposure variable. Plasma triglycerides were natural-log transformed in order
to meet the modeling assumption of normally distributed residuals. For simplicity and
comparability, models for all four lipid parameters were adjusted for the same covariate set.
Covariates were selected through the construction of a directed acyclic graph (DAG)
representing the existing literature, and the identification of a minimally sufficient set of
variables to control confounding. The DAG was primarily based on expected confounders of
the PFAS-HDL association but was also generalizable to the other lipid outcomes. The
minimally sufficient adjustment set was identified using DAGitty v1.0 (www.dagitty.net).
All covariates were modeled as categorical variables to allow for non-linear associations.
The categorization of covariates was as follows: maternal age (<24, 25–29, 30–34, >=35
years); pre-pregnancy BMI (<25, 25–29.99, >=30 kg/m2); maternal education (less than high
school, completed high school, some college, 4 or more years of college); smoking at mid-
pregnancy (yes/no), oily fish consumed (0–3.0, 3.1–7.5, 7.6–14.9, 15–100 g/day);
gestational age at blood draw (12–16, 17–18, 19–20, 21–37 weeks); nulliparous or most
recent interpregnancy interval (nulliparous, 4–23, 24–47, 48–245 months); and
breastfeeding duration in previous pregnancy (nulliparous or <1, 1–5, 6–11, 12–17, 18–36
months). Subjects were excluded from the analysis if they had missing values for any
modeled covariates. Additionally, a sensitivity analysis was performed with the inclusion of
weight gain (kg) from pre-pregnancy to mid-pregnancy as a continuous covariate, although
this variable was not part of the original DAG.
Spearman rank-order correlations were calculated between each pair of PFASs. In order to
explore the possible influence of confounding by other, correlated PFASs in single-pollutant
models, a multiple-pollutant model was estimated for HDL cholesterol. In the multiple-
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pollutant model, all seven PFASs quantifiable in >50% of samples were included in the
same model as natural-log transformed continuous variables. The variance inflation factors
for each of the exposures in this model were examined to assess multicollinearity. All
statistical analyses were performed using SAS 9.3 (SAS Institute, Cary, NC).
3. Results and Discussion
3.1. Measured PFAS concentrations compared to previous studies
Of the nineteen PFASs measured, only seven were quantifiable in greater than 50% of
samples: PFOA, PFNA, PFDA, PFUnDA, PFHxS, PFHpS, and PFOS. Further analyses
were restricted to these seven compounds. PFDA was quantifiable in 70% of samples, while
the six other PFASs were quantifiable in at least 88% of samples (Table 2). PFOS and
PFOA were quantifiable in 100% of samples. The highest median concentration was
observed for PFOS (13.03 ng/mL), followed by PFOA (2.25 ng/mL), then PFHxS (0.60 ng/
mL), PFNA (0.39 ng/mL), PFUnDA (0.22 ng/mL), PFHpS (0.13 ng/mL), and finally PFDA
(0.09 ng/mL). The median plasma concentrations of the seven PFASs in this study were
comparable to reported serum levels from 2006 in Norway (Haug et al., 2009b) and
somewhat lower than reported serum levels from the United States in the same year (Kato et
al., 2011). Plasma and serum measurements of PFASs have been shown to be approximately
equal for a particular subject at a given time (Ehresman et al., 2007). Therefore the PFAS
concentrations measured in the current study are comparable to the magnitude of exposure
observed in previous studies of background-exposed populations.
A number of the PFASs demonstrated moderate to high pairwise correlations (Table 3). The
most strongly correlated PFASs were PFNA and PFDA (ρ=0.71). The least correlated
PFASs among the seven were PFUnDA and PFHpS (ρ=0.17). In general, the sulfonates
(PFHxS, PFHpS, PFOS) were relatively highly correlated with one another (ρ=0.53–0.60)
while the pairwise correlations among the carboxylates (PFOA, PFNA, PFDA, PFUnDA)
were more variable (ρ=0.26–0.71).
3.2. Distribution of lipid outcome variables
The median plasma concentration for total cholesterol was 211 mg/dL, for HDL was 67 mg/
dL, for LDL was 125 mg/dL, and for triglycerides was 124 mg/dL (Table 4). The
distribution of plasma total cholesterol, HDL cholesterol, and LDL cholesterol was
approximately normal while the distribution of plasma triglycerides demonstrated positive
skew. Triglycerides were therefore natural-log transformed in subsequent analyses. Two
implausibly low values for HDL cholesterol (2.5 mg/dL) and triglycerides (2.5 mg/dL) were
treated as missing. Lipid concentrations were moderately to highly correlated with one
another. The highest correlation was observed between total cholesterol and LDL (ρ=0.88),
while total cholesterol was only moderately correlated with HDL (ρ=0.36) and ln-
triglycerides (ρ=0.35). HDL and LDL were very weakly correlated (ρ=0.06, p>0.05), while
HDL and ln-triglycerides were inversely correlated (ρ= −0.29, p<0.05).
3.3. PFASs and total cholesterol
Total cholesterol was positively associated with ln-PFOS as a continuous variable (Table 5).
Each ln-unit increase in PFOS was associated with an increase of 8.96 mg/dL (95%
CI=1.70, 16.22) in total cholesterol. For each IQR-unit increase in ln-PFOS, total cholesterol
increased by 4.25 mg/dL (95% CI=0.81, 7.69). The latter change represents an increase of
2.0% over the median concentration of total cholesterol in this population. The Pearson
correlation between ln-PFOS and total cholesterol was 0.08 (p<0.05). The third and fourth
quartiles of PFOS had elevated total cholesterol as compared to the first quartile, but the
confidence intervals were imprecise. None of the other PFASs had notable linear
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associations with total cholesterol; in addition, the quartile estimates generally did not
provide support for monotonic dose-response relationships between PFASs and total
cholesterol.
Several previous studies have described positive associations between PFASs and total
cholesterol. Both PFOA and PFOS have been associated with total cholesterol in a general
population sample (Nelson et al., 2010) and among highly PFOA-exposed adults (Steenland
et al., 2009) and children (Frisbee et al., 2010). Among highly exposed, predominantly male,
adult workers PFOA was associated with total cholesterol (Costa et al., 2009; Olsen et al.,
2003; Sakr et al., 2007). There is prior evidence that associations with total cholesterol may
vary among PFASs. One study of non-pregnant adults in the general U.S. population
described positive associations between PFOS, PFOA, PFNA and total cholesterol, but an
inverse association between PFHxS and total cholesterol (Nelson et al., 2010); while a
recent study of non-pregnant adult Canadians reported a positive association between
PFHxS and total cholesterol, but no significant associations between PFOA or PFOS and
total cholesterol in weighted analyses (Fisher et al., 2013).
3.4. PFASs and HDL cholesterol
In adjusted quartile analyses, all seven PFASs had higher HDL cholesterol associated with
the highest quartile of exposure, relative to the lowest quartile of exposure (or, in the case of
PFDA, associated with concentration at or above the median versus below the median)
(Table 5). Additionally, PFOS, PFNA, PFDA, PFUnDA, and PFHxS showed positive linear
associations with HDL cholesterol in adjusted models. The strongest evidence supporting a
monotonic dose-response relationship with HDL was observed for PFUnDA, which had the
highest quartile-specific associations as well as the largest associated change in HDL. For
each natural log-unit increase in PFUnDA, HDL increased by 4.05 mg/dL (95% CI=2.75,
5.35). For each IQR-unit increase in ln-PFUnDA, HDL increased by 3.71 mg/dL (95%
CI=2.52, 4.89). This change represents an increase of 5.5% over the median concentration of
HDL cholesterol in this sample.
The other six PFASs also demonstrated some evidence of an exposure-response relationship
with HDL in adjusted quartile analyses, although in general the association was driven by
the highest quartile of exposure. Each IQR-unit increase in ln-PFNA was associated with an
increase of 1.66 mg/dL HDL (95% CI=0.57, 2.76); each IQR-unit increase in ln-PFDA was
associated with an increase of 2.55 mg/dL HDL (95% CI=1.22, 3.88); and each IQR-unit
increase in ln-PFOS was associated with an increase of 2.08 mg/dL HDL (95% CI=1.12,
3.04).
The observed associations between PFASs and HDL cholesterol are consistent with the
findings of some previous cross-sectional studies, but inconsistent with others. Serum PFOS
has been positively associated with HDL cholesterol among non-pregnant Inuit adults
(Chateau-Degat et al., 2010) as well as among children and adolescents from a highly
PFOA-exposed community in Ohio and West Virginia (Frisbee et al., 2010). However, other
studies have reported no association between PFASs and HDL cholesterol (Nelson et al.,
2010; Steenland et al., 2009), and one recent study of highly PFOA-exposed male workers
in China reported an inverse association between PFOA and HDL (Wang et al., 2012).
Adjustment for plasma albumin concentration (quartiles) tended to reduce the magnitude of
the associations between each PFAS quartile and HDL cholesterol (Supplemental Table).
On average, the difference in HDL cholesterol between the lowest and highest quartile of
PFAS was reduced by 15% with the inclusion of plasma albumin in the model. The
coefficients for the linear associations between continuous natural-log transformed PFAS
variables and continuous HDL were attenuated by 16% on average, but remained elevated.
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As multiple PFASs tend to be correlated with one another, it is possible that the results
observed in single-exposure models are partially due to the confounding influence of one or
more correlated PFAS species. All seven PFASs were included as continuous natural-log
transformed exposure variables in the same model to determine their mutually-adjusted
associations with HDL. The coefficients for all PFASs were attenuated, with the exception
of PFUnDA, which remained strongly associated with HDL (Figure 1). The change in HDL
for each IQR-unit of PFNA was reduced from 1.66 mg/dL (95% CI=0.57, 2.76) to −1.19
mg/dL (95% CI= −2.97, 0.59) in the adjusted multiple pollutant model. The change in HDL
for each IQR-unit of PFUnDA decreased only slightly from 3.71 mg/dL (95% CI=2.52,
4.89) to 3.63 mg/dL (95% CI=1.88, 5.39). The influence of including the other six PFASs in
each model was generally much stronger than the influence of adjustment for other
covariates. The multiple pollutant model did not show evidence of multicollinearity; all
variance inflation factors for the PFAS variables were <4. It is notable that PFUnDA, with
an alkyl chain length of 10, was the longest-chain PFAS examined here, but we are not
aware of research suggesting that PFUnDA has higher potency or biological activity in
humans relative to the shorter-chain PFASs.
3.5. PFASs and LDL cholesterol
In adjusted models for LDL cholesterol, the beta-coefficient for an ln-unit change in PFOS
was elevated, but the confidence interval was wide and included the null (Table 5); each
IQR-unit shift in ln-PFOS was associated with a change of 3.07 mg/dL LDL (95% CI=
−0.03, 6.18). The second quartile of PFOS concentration was associated with a decrease in
LDL concentration relative to the first quartile, while the third and fourth quartiles of PFOS
concentration were associated with elevated LDL. None of the other six PFASs were
associated with LDL.
The existing literature on this topic is inconclusive, with previous studies reporting both
positive (Frisbee et al., 2010; Sakr et al., 2007; Steenland et al., 2009) and no associations
between PFASs and LDL cholesterol (Chateau-Degat et al., 2010). In the present study,
PFOS was positively associated with both total cholesterol and HDL cholesterol, and less
strongly associated with LDL cholesterol. This finding of the same direction of association
with both HDL and LDL cholesterol is not necessarily paradoxical. While certain
medications and foods can increase HDL cholesterol while decreasing LDL cholesterol
(Mensink et al., 2003; Soudijn et al., 2007), other foods such as saturated fats can increase
both HDL and LDL cholesterol (Hayek et al., 1993). Positive associations between PFOS
and both HDL and LDL cholesterol were also observed in a previous study among children
and adolescents (Frisbee et al., 2010).
3.6. PFASs and triglycerides
Linear associations between PFASs and triglycerides were not observed (Table 5). The
fourth quartile of PFUnDA concentration was associated with small decrease in ln-
triglycerides (−0.08 ln-mg/dL, 95% CI= −0.16, −0.01) relative to the first quartile.
Additionally, the second quartile of PFHpS concentration was associated with slightly lower
ln-triglycerides (−0.08 ln-mg/dL, 95% CI= −0.15, −0.01) relative to the first quartile. None
of the other PFASs were associated with triglycerides in quartile-based or continuous
models.
Previous studies have reported positive associations between PFOA and PFOS and
triglycerides, among highly exposed workers (Olsen et al., 2003) and among adults in the
highly PFOA-exposed Ohio and West Virginia population (Steenland et al., 2009). One
occupational study reported no association between PFOA and triglycerides (Sakr et al.,
2007).
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Restricting the analysis to the 525 women with complete covariate and outcome data who
were selected without regard to subfecundity produced quartile effect estimates that were
similar to those produced by the weighted models, although the confidence limits were
wider due to the smaller sample size (results not shown). Additional inclusion of weight gain
(kg) from pre-pregnancy to mid-pregnancy as a continuous covariate did not materially
change the interpretation of any effect estimates (results not shown), and therefore was not
included in the adjusted models for which results are shown.
3.8. Interpretation of findings
This study is the first to specifically examine associations between PFASs and lipids in
pregnant women. Some previous studies (Chateau-Degat et al., 2010; Nelson et al., 2010)
excluded pregnant women, who are known to have altered lipid metabolism relative to non-
pregnant women. Notably, in normal pregnancy total cholesterol rises 25–50% over non-
pregnant levels (Piechota and Staszewski, 1992) and triglycerides are typically elevated
200–400% times over pre-pregnant levels by late pregnancy (Fahraeus et al., 1985; Sattar et
al., 1997b). HDL cholesterol also increases by approximately 40% over non-pregnant levels
(Fahraeus et al., 1985). The composition of HDL particles also changes during pregnancy,
such that each particle contains a greater proportion of cholesterol and acylglycerols, but
without an increase in phospholipid content (Aurell and Cramer, 1966).
PFOA and PFOS concentrations in pregnant women have been reported to be somewhat
lower than in non-pregnant women (Woodruff et al., 2011); in one study this difference
persisted after adjustment for hemoglobin/hematocrit ratio as well as demographic and
lifestyle factors (Javins et al., 2013). The observed differences may be due to the residual
confounding effects of normal plasma volume expansion during pregnancy, but may also
suggest transfer of PFASs to the fetus, or increased excretion of PFASs during pregnancy
(Loccisano et al., 2013). Given these differences in both lipids and PFASs during pregnancy,
it is plausible that whatever causal or non-causal mechanism leads to observed associations
between PFASs and lipids, the associations may differ in pregnant women relative to non-
pregnant women.
The biological mechanism that may lead to positive associations between plasma PFAS
concentrations and lipids in humans is largely unknown. PFAS are known to activate
PPARα, a receptor involved in regulating gene expression related to lipid and glucose
metabolism, but the activation of this receptor in humans tends to produce lower lipid
concentrations (Hertz et al., 1995). While some of the toxic effects of PFOA in animals are
believed to operate through activation of PPARα, evidence suggests that the toxicity of
PFOS may occur through alternate mechanisms, independent of PPARα (Abbott et al.,
2009; Abbott et al., 2007). Recently, toxicologists have begun to study PFASs other than
PFOA and PFOS, and have demonstrated varying strength of PPARα activation associated
with PFASs of different chain lengths (Wolf et al., 2012). The relative proportion of
biological effects due to PPARα-dependent mechanisms and PPARα-independent
mechanisms may vary across PFASs.
The investigation of potential health effects due to relatively low-concentration plasma
contaminants such as PFUnDA, PFNA, and PFHxS may be particularly important given that
the effects of human exposure to these PFASs have not received as much attention in the
literature as the effects of exposure to PFOA and PFOS. While the measured plasma
concentrations of these PFASs were substantially lower in our study than the concentrations
of PFOA and PFOS, serum concentrations of PFNA may still be increasing in some
populations (Haug et al., 2009b; Kato et al., 2011). Moreover, certain PFASs that previously
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appeared in human serum at low concentrations, such as PFHxS, have been used to replace
PFOS in household stain-proofing and other applications following the phase-out of PFOS
in 2000–2002, and therefore we may expect higher human exposures in the future (Beesoon
et al., 2012; Glynn et al., 2012).
A limitation of this study is the cross-sectional design, which does not allow causal
interpretation of the findings. Non-causal explanations for the findings may include
unmeasured confounding or pharmacokinetics. A recent laboratory study explored whether
previously observed cross-sectional associations between PFASs and plasma lipid
parameters could be explained by the distribution of PFASs into lipoprotein fractions, and
concluded that this partitioning was not a sufficient explanation for the dose-response
associations observed (Butenhoff et al., 2012). However, the same study found that of the
small proportion of each PFAS (for example, <25% of PFOS) that resided in the non-
lipoprotein-depleted portion of the plasma, a somewhat larger percentage was recovered
from the HDL subfraction relative to the LDL and VLDL subfractions (Butenhoff et al.,
2012), raising the possibility of a special affinity between HDL and some PFASs.
Researchers may wish to further examine whether this affinity could account for the
association observed here between HDL and PFASs in plasma.
Another potential limitation of this study is the use of non-fasting plasma lipid
measurements. Fasting for 8–12 hours is typically recommended prior to lipid screening.
However, researchers have observed minimal changes in lipid profiles following typical
food intake (Langsted et al., 2008). Additionally, non-fasting triglycerides may be more
strongly associated with cardiovascular disease risk in women than fasting triglycerides
(Bansal et al., 2007). Our study also employed a single measurement of plasma lipid
concentrations. As these measurements may vary over time, multiple measures are preferred
to establish lipid profiles for cardiovascular risk (Davis et al., 1990).
PFASs have been previously correlated with other environmental pollutants such as PCBs
and PBDEs (Haug et al., 2010), possibly due to common exposure sources such as fish and
shellfish. We adjusted for daily intake of oily fish in our models; however we cannot
exclude the possibility of residual confounding due to measurement error in fish intake, or to
unmeasured environmental pollutants. Our study did not consider dietary components other
than oily fish that may influence lipid concentrations.
In general, the findings lend only modest support to a possible mechanism by which PFAS
concentrations during pregnancy may be related to adverse pregnancy outcomes. Lipid
disturbances in early and late pregnancy associated with preeclampsia include elevated
triglycerides (Baker et al., 2009; Sattar et al., 1997a), as well as higher total cholesterol and
LDL, and typically lower HDL cholesterol (Bayhan et al., 2005; Enquobahrie et al., 2004),
although one study noted slightly higher HDL at mid-pregnancy among women who
subsequently developed severe preeclampsia as compared to controls (Baker et al., 2009).
We found no evidence of elevated triglycerides associated with PFAS concentrations in
pregnant women. The positive associations we observed between multiple PFASs and HDL
cholesterol are not consistent with elevated risk of preeclampsia. However, we did observe a
positive linear association between PFOS and total cholesterol, and higher total cholesterol
is associated with elevated risk of preeclampsia. We plan to directly examine the
associations between mid-pregnancy PFASs and preeclampsia in another study within the
MoBa cohort.
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This study provides evidence of PFAS-specific associations with lipids in pregnant women.
Specifically, plasma PFOS concentration during pregnancy was positively associated with
total cholesterol, and multiple PFASs were positively associated with HDL cholesterol.
While the latter finding is not consistent with lipid profiles that have been associated with
adverse pregnancy outcomes, the association between PFOS concentrations and cholesterol
during pregnancy merits further investigation in a longitudinal study to determine whether
or not it is likely to be causal. Elevated total cholesterol during pregnancy is associated with
adverse pregnancy outcomes, including preeclampsia, which can result in harm to the
mother and developing fetus.
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• We examined associations between perfluoroalkyl substances and lipids in
pregnancy.
• Plasma PFOS was positively associated with total cholesterol among pregnant
women.
• Seven perfluoroalkyl substances were positively associated with HDL
cholesterol.
• Multiple pollutant models reduced all associations with HDL except PFUnDA.
• Cholesterol findings may suggest a possible mechanism linking PFOS to
preeclampsia.
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Weighted linear regression coefficients for single and multiple pollutant models of the
association between natural log-transformed PFASs (ln-ng/mL) and HDL cholesterol (mg/
dL).
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Table 1
Characteristics of 891 pregnant women enrolled in the Norwegian Mother and Child Cohort Study (2003–
2004) and previously selected for a case-control study of subfecundity
N %
Age (years)
  19–24 54 6
  25–29 262 29
  30–34 399 45
  35–44 176 20
Pre-pregnant body mass index (kg/m2)
  14.9–<25.0 529 59
  25.0–<30.0 241 27
  30.0–45.4 121 14
Education completed
  Less than high school 74 8
  Completed high school 287 32
  Some college 373 42
  4 or more years college 157 18
Smoking at mid-pregnancy
  Yes 72 8
  No 819 92
Oily fish consumed (g/day)
  0–3.0 230 26
  3.1–7.5 224 25
  7.6–14.9 216 24
  15–100 221 25
Gestational age at blood draw (weeks)
  12–16 151 17
  17–20 653 73
  21–37 87 10
Trimester of pregnancy at blood draw
  First (12–13 weeks) 6 0.7
  Second (14–26 weeks) 881 99
  Third (27–37 weeks) 4 0.4
Time to pregnancy (months)
  <3 292 33
  3–6 146 16
  7–12 54 6
  >12 397 45
Previous live births or stillbirths
  0 447 50
  1 308 35
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N %
  2 111 12
  3 + 25 3
Interpregnancy interval (months)
  No previous births/stillbirths 447 50
  4–23 106 12
  24–47 178 20
  48–245 160 18
Breastfeeding duration in previous
pregnancy (months)
  No previous births/stillbirths 447 50
  <1 114 13
  1–5 39 4
  6–11 146 16
  12–17 120 13
  18–36 25 3
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